CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation.
CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法在治疗血液恶性肿瘤方面取得了重大进展,但其疗效往往受到T细胞功能欠佳的限制,表现为抗肿瘤能力弱和缺乏持久性。免疫突触是T细胞功能的关键决定因素,受CD58-CD2轴影响。T细胞上CD2表达的动态调控影响CAR介导的免疫突触质量,进而影响CAR-T 细胞的功能结局和分化。我们的研究表明,CD2表达水平与CAR-T 细胞形成的免疫突触质量及其抗肿瘤效力密切相关。外源性CD2补充增强CAR-T 细胞形成高质量突触的能力,减少T细胞耗竭,并提高持续抗肿瘤疗效。此外,异位CD2表达增加CAR-T 细胞对低密度抗原的敏感性。因此,在CAR-T 细胞中补充CD2是提高CAR-T 细胞疗法疗效的一种有前景的策略。
CAR-T-cell therapy has made significant strides in treating hematological malignancies, yet its efficacy is often hampered by suboptimal T-cell functionality, marked by weak antitumor capabilities and a lack of durability. The immunological synapse, a key determinant of T-cell function, is influenced by the CD58-CD2 axis. The dynamic regulation of CD2 expression on T cells impacts the quality of CAR-mediated immunological synapses, affecting CAR-T-cell functional outcomes and differentiation.
Our study demonstrated that CD2 expression levels are closely linked to the quality of immunological synapses formed by CAR-T cells and their antitumor potency. Exogenous CD2 supplementation enhances the ability of CAR-T cells to form high-quality synapses, reduces T-cell exhaustion, and increases sustained antitumor efficacy.
Additionally, ectopic CD2 expression increases CAR-T-cell sensitivity to low-density antigens.
Thus, replenishing CD2 in CAR-T cells is a promising strategy to increase the therapeutic efficacy of CAR-T-cell therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。